IQVIA Holdings Inc. $IQV Shares Sold by Tranquility Partners LLC

Tranquility Partners LLC decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 17.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,613 shares of the medical research company’s stock after selling 2,264 shares during the quarter. Tranquility Partners LLC’s holdings in IQVIA were worth $1,673,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. Pacer Advisors Inc. boosted its position in shares of IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after purchasing an additional 798,534 shares during the period. Hawk Ridge Capital Management LP acquired a new position in shares of IQVIA in the 1st quarter valued at $77,096,000. Nuveen LLC acquired a new position in shares of IQVIA in the 1st quarter valued at $76,328,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of IQVIA in the 2nd quarter valued at $61,585,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 2.3%

IQV opened at $198.35 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The business has a 50-day moving average of $189.02 and a 200-day moving average of $168.19. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $33.72 billion, a PE ratio of 28.70, a price-to-earnings-growth ratio of 2.18 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the business earned $2.64 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on IQV. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday. Robert W. Baird raised their price objective on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Cowen restated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial raised their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Finally, HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $195.00 to $235.00 in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $236.45.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.